Literature DB >> 19681707

Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.

Jodi M Lestner1, Steven A Roberts, Caroline B Moore, Susan J Howard, David W Denning, William W Hope.   

Abstract

We explored concentration-toxicity relationships for itraconazole among 216 patients. Logistic regression revealed a progressive increase in the probability of toxicity with increasing concentrations of itraconazole. Classification and regression tree analysis suggested that 17.1 mg/L of itraconazole (measured using a bioassay) was the concentration level at which the population of patients was separated into 2 groups, each with a high and a low probability of toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681707     DOI: 10.1086/605499

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

1.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Randomised Comparison of Safety Profile and Short Term Response of Itraconazole, Voriconazole and Amphotericin B in the Management of Chronic Invasive Fungal Rhinosinusitis.

Authors:  Santosh Debbarma; Rijuneeta Gupta; Sourabha K Patro; Ashok K Gupta; Promila Pandhi; Nusrat Shafiq
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-01-24

Review 3.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

4.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

5.  A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics.

Authors:  David L Hava; Lisa Tan; Patrick Johnson; Aidan K Curran; Jason Perry; Steve Kramer; Katie Kane; Pauline Bedwell; Gary Layton; Clarie Swann; Dennis Henderson; Naimat Khan; Lucy Connor; Litza McKenzie; Dave Singh; James Roach
Journal:  Br J Clin Pharmacol       Date:  2020-01-16       Impact factor: 4.335

Review 6.  Current concepts in antifungal pharmacology.

Authors:  Russell E Lewis
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

7.  A report of a successfully treated case of ABPA in an HIV-infected individual.

Authors:  Valliappan Muthu; Ritesh Agarwal
Journal:  BMJ Case Rep       Date:  2014-11-09

8.  Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.

Authors:  David Andes; Laura Kovanda; A Desai; Therese Kitt; M Zhao; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

9.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 10.  Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.

Authors:  Jodi M Lestner; P Brian Smith; Michael Cohen-Wolkowiez; Daniel K Benjamin; William W Hope
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.